Discover the benefits of liquid-based cytology (LBC) and the HPV test. Learn how these tests detect cervical cancer, infections, and who can receive them for free under the National Health Fund (NFZ).
Table of Contents
- What is Liquid-Based Cytology (LBC) and How Does it Work?
- HPV Test – When is it Worth Doing Together with LBC Cytology?
- Advantages of Liquid-Based Cytology and HPV Testing in Cervical Cancer Prevention
- Which Infections and Changes Does Liquid-Based Cytology (LBC) Detect?
- Price, Availability and Funding of LBC Cytology and HPV Testing by NFZ
- How to Prepare for the Tests and Interpret LBC Cytology Results?
What is Liquid-Based Cytology (LBC) and How Does it Work?
Liquid-based cytology, also known as LBC, is a modern screening method used to detect early cancerous and precancerous changes in the cervix. It is an upgraded version of traditional smear cytology and is increasingly recognized by doctors and patients worldwide, including Poland. The distinctive feature of liquid-based cytology is the way the collected material is prepared and analyzed, which significantly differs from the traditional approach. In classic cytology, cellular material from the cervix is transferred directly onto a glass slide, which can lead to artifacts, uneven material distribution, and loss of the sample, thereby increasing the risk of diagnostic errors or inadequate specimens. In contrast, with LBC, cells collected with a special brush are immediately placed in a container with a fixative solution. This container is sent to the laboratory, where the material undergoes filtering and purification to remove contaminants, mucus, blood, and bacteria. The resulting clean sample is applied automatically onto a slide, creating a uniform layer of cells, which significantly improves microscopic evaluation and allows detection of even subtle early changes. As a result, liquid-based cytology provides higher sensitivity and a lower false-negative rate compared to the conventional cytology. An additional benefit of LBC is that the same sample can be used for molecular studies, such as tests for HPV (Human Papilloma Virus), bacterial, or even genetic tests without taking another sample from the patient. This minimizes discomfort for women and improves the effectiveness of cervical cancer prevention.
The process of collecting a sample for LBC is not significantly different from the traditional method – the doctor or midwife inserts a speculum into the patient’s vagina and collects a swab from the cervix using a dedicated, soft cytology LBC brush. After sampling, the brush is dipped into the fixative and sent to the diagnostic laboratory. The prepared sample is fully protected from drying out and degradation, which prolongs the time lab staff have for analysis. Using advanced filtration and cytocentric equipment, lab technicians prepare high-quality, transparent, and uniformly stained samples. This is crucial for the cytopathologist, who can more easily and rapidly assess atypical cells, viral HPV changes, and other abnormalities. Moreover, LBC allows automating many sample preparation stages, further reducing the risk of human or reagent errors. Consequently, LBC yields a higher percentage of reliable results and greater effectiveness in detecting early cervical neoplasia – including both low-grade (LSIL) and high-grade (HSIL) intraepithelial lesions, as well as inflammatory and glandular changes. LBC is recommended for women of all ages, especially those at increased risk of cervical cancer, such as those infected with HPV, those with prior abnormal cytology results, or those with weakened immunity. Importantly, despite being newer and more expensive than conventional cytology, LBC is increasingly available for free as part of NFZ preventive health programs, offering women in Poland more effective protection of their health and lives.
HPV Test – When is it Worth Doing Together with LBC Cytology?
The HPV test (Human Papillomavirus) together with liquid-based cytology (LBC) is an increasingly used combination that significantly enhances the effectiveness of cervical cancer prevention. The most important advantage of the HPV test is its ability to directly detect HPV DNA in cells collected from the cervix. Persistent infection with oncogenic types of HPV is the main cause of precancerous changes and cervical cancer. Therefore, the HPV test is particularly recommended for women over 30, when most transient, non-intervention-requiring infections have spontaneously resolved. Performing LBC and HPV testing together provides an accurate assessment of both cervical cell status and risk factors – the virus. This offers the doctor a comprehensive overview – both the morphological state of the cells (cytology) and the possible cause of any abnormalities (HPV test). This parallel approach, called co-testing, is recommended by gynecological societies and international guidelines, as it increases the sensitivity of detecting precancerous changes to nearly 100%. Additionally, modern LBC enables both tests from one sample, which enhances patient comfort and reduces waiting times. Testing can also be considered if the cytology result is abnormal (ASC-US or higher group), after treatment for precancerous conditions, or in people with weakened immunity, increasing diagnostic effectiveness and reducing the need for repeated invasive procedures.
Modern cervical cancer prevention is based on an individualized approach, so both the timing and indications for HPV testing with LBC should be discussed with a physician. The HPV test is mainly recommended for women aged 30–65, regardless of previous cytology results, every five years, as a screening complement. This allows for the detection of asymptomatic viral infections years before visible cytology changes. It is especially indicated in women with ambiguous cytology results (e.g., ASC-US, LSIL) or after prior abnormal results, to confirm disease risk and determine the need for further diagnostics or therapy. Moreover, simultaneous HPV and LBC testing is optimal for high-risk groups – those with HIV, post-transplant or long-term immunosuppression, or with a family history of cervical cancer. The introduction of partially subsidized NFZ programs enables more Polish women to undergo both tests free or with substantial funding, eliminating financial barriers to advanced prevention. Performing HPV and LBC tests simultaneously in healthy, sexually active women increases diagnostic safety — enabling early detection of both “silent” oncogenic HPV infections, as well as the smallest cellular changes that may lead to cancer development. Both tests, although different in scope and mechanisms, complement each other: a negative HPV test result allows for extending the interval until the next screening to up to five years (per guidelines), while abnormalities require prompt further diagnostics, such as colposcopy or biopsy. In summary, the combination of HPV and LBC tests helps avoid unnecessary overtesting or missing serious changes, providing the most effective cervical cancer prevention currently available in Poland.
Advantages of Liquid-Based Cytology and HPV Testing in Cervical Cancer Prevention
LBC and HPV testing are currently among the most effective tools in the prevention of cervical cancer, greatly surpassing traditional methods in both accuracy and patient comfort. The main advantage of LBC is its higher diagnostic sensitivity: the collected cells are almost entirely transferred to the laboratory, and the liquid fixative prevents damage, clumping, or drying out, which reduces the number of unsatisfactory or ambiguous results. Advanced filtration technology eliminates contaminants and elements interfering with analysis, thus pathomorphologists receive clear, evenly distributed specimens, facilitating detection of even very early intraepithelial changes or atypical cells indicating cervical cancer development. LBC is also advantageous because, from the same sample, additional molecular tests can be run, such as the aforementioned HPV test or analyses for other intimate infections. Importantly, fewer samplings are needed, benefiting patient comfort and safety – the biological material does not need to be recollected, and diagnostics are precise and fast. From a medical perspective, LBC streamlines the entire diagnostic process, shortens reporting time, and reduces the need for repeat testing. High-quality samples minimize the risk of misinterpretation or overlooking minor, troubling changes, directly contributing to early detection of precancerous and cancerous cervical changes.
The HPV test is another key modern element in cervical cancer prevention, enabling identification of asymptomatic infections caused by oncogenic types of the human papillomavirus, the main cause of cervical cancer. Unlike traditional cytology, which assesses only cell morphology, the HPV test directly detects the presence of viral genetic material in epithelial cells. This is crucial because HPV infections can be asymptomatic for years and still lead to cancerous changes. Modern genotype identification methods allow precise risk estimation and proper selection of monitoring and management. Combining LBC cytology with HPV testing in screening detects not only women with abnormal cytology but also those carrying high-risk HPV, even when cytology is still normal. This two-step approach successfully minimizes the risk of missed abnormalities and significantly boosts the chance for complete cure if precancerous changes are found. Moreover, the greater sensitivity of the HPV test allows for longer intervals between check-ups for women with normal results while maintaining a high safety standard. Practically, this means less stress and greater comfort, as well as reducing the strain on the healthcare system. Both methods – LBC and HPV test – promote an individualized risk approach, making it easier to assign patients to further treatment or more frequent monitoring. Their introduction to NFZ-funded programs has significantly improved access to cervical cancer prevention, including for those living in smaller towns and rural regions. It’s worth highlighting that the comprehensive approach combining both LBC and HPV tests is recommended by leading global and Polish medical societies as the gold standard for gynecological care. As a result, women using these modern methods are offered true early detection of potential threats, accurate health monitoring, and highly effective protection against one of the most dangerous female cancers.
Which Infections and Changes Does Liquid-Based Cytology (LBC) Detect?
Liquid-based cytology (LBC) is an advanced diagnostic technology whose precision and effectiveness allow a broad spectrum of infection and pathology identification within the cervix. The main advantage of LBC is obtaining much higher quality samples compared to conventional cytology. The accuracy results from the sample preparation process – cells are stored and transported in a special fixative solution, almost entirely eliminating problems of improper material distribution and artifacts that can complicate microscopic assessment. This allows the pathologist to better evaluate the epithelial cell status and identify both typical precancerous changes and infections. LBC enables early detection of dysplastic changes, such as ASC-US (atypical squamous cells of undetermined significance), LSIL (low-grade squamous intraepithelial lesion), and HSIL (high-grade squamous intraepithelial lesion). Identifying these changes is key as it allows for swift further diagnostics and treatment, minimizing the risk of invasive cervical cancer. Owing to higher sensitivity, LBC more easily detects subtle abnormalities – atypical cells, koilocytosis, dysplasia development, and early neoplasia manifestations. This method plays a significant role in monitoring patients after precancerous treatment or conization, allowing strict control over possible pathology relapses.
Detecting Viral, Bacterial, and Fungal Infections
Besides detecting cancerous and precancerous changes, a key application of LBC is identifying various genital tract infections. The most important risk factor for cervical cancer is chronic human papillomavirus (HPV) infection, especially oncogenic types, but LBC also enables detection of cytopathic effects of other viruses. High-quality preparations can reveal changes indicating infection with herpes simplex virus type 2 (HSV-2) or cytomegalovirus (CMV), though these have less oncological significance. In addition, LBC can recognize bacteria-driven infections such as Gardnerella vaginalis (responsible for bacterial vaginosis), plentiful leukocytes and clue cells, as well as Chlamydia trachomatis or Neisseria gonorrhoeae. The high-resolution sample also reveals fungal infections, most commonly caused by Candida albicans – typical mycelial cells and blastospores are clearly visible. LBC also assists in identifying trichomoniasis (Trichomonas vaginalis), recognizable by presence of the parasite among epithelial cells. These wider interpretation options result from better sample preservation and uniform cell distribution, appreciated by both cytologists and gynecologists. Unique to LBC is the option of using the same specimen for molecular tests – allowing simultaneous detection of HPV DNA or other pathogens, and even testing for genetic mutations relevant to cancer risk. Additionally, LBC helps track changes related to epithelial regeneration, inflammation (such as cervicitis), or perimenopausal atrophy, diagnostically important across all age groups. Finally, liquid sample archiving enabled by LBC ensures test repeatability and easy inter-laboratory consultation, further increasing diagnostic precision and health safety for women participating in cervical cancer screening.
Price, Availability and Funding of LBC Cytology and HPV Testing by NFZ
In recent years, access to modern diagnostics such as liquid-based cytology (LBC) and HPV testing has systematically increased in Poland, marking a significant step toward improving cervical cancer prevention. The price for these tests in private clinics varies by region and facility standards – LBC usually costs 80–150 PLN, while basic oncogenic HPV testing can range from 120 to even 250 PLN. Combined test packages covering both methods or expanded HPV genotyping may exceed 300–350 PLN. Nevertheless, growing public awareness and the need for more effective women’s health protection means that more Polish women are choosing such comprehensive options at least every few years. Privately paid tests offer not only cutting-edge technologies and more flexible scheduling but often short waiting times for results and the chance for detailed consultation with a physician. Despite these advantages, the price remains a significant barrier for many women, especially considering the regularity recommended in screening programs.
Access to LBC cytology and HPV testing has been extended under National Health Fund (NFZ) reimbursed programs, increasingly reaching smaller towns and high-risk women. Liquid cytology is gradually appearing as an alternative to standard slide cytology in the population cervical cancer prevention program. Women aged 25 to 59 can have cytology reimbursed every three years as part of screening (provided they didn’t have it in this period). In many provinces, LBC is also available in public healthcare as an alternative – depending on laboratory accessibility in a given clinic. HPV test reimbursement is currently mostly possible for women with abnormal or ambiguous cytology, or after treatment of cervical conditions that require follow-up; however, it’s not available universally in population screening – HPV test as a primary screening tool is managed as a pilot in selected regions. Reimbursement for both tests is crucial in minimizing discrepancies in advanced prevention access between large urban and rural areas, and among different social groups. Dedicated prevention campaigns, open days in clinics, or mobile sampling points let women have LBC or HPV tests without referral. Also, if a patient has a referral from a gynecologist or medical justification (such as alarming symptoms or previous abnormal results), both tests can be done under NFZ funds outside the screening program. With the dynamic development and rise of molecular testing, many cities are implementing locally co-funded projects that allow broader and more convenient access to LBC cytology and HPV testing. The level of reimbursement and precise path to free testing may differ depending on region and Ministry of Health/NFZ guidelines, so it’s advisable to check opportunities in your area. Thanks to education and broader public funding, the popularity of both methods is projected to rise, which will tangibly lower cervical cancer incidence and improve Polish women’s quality of life.
How to Prepare for the Tests and Interpret LBC Cytology Results?
Proper preparation for a liquid-based cytology test (LBC) is key for a reliable result, which may be crucial for a woman’s health. Ideally, the test is performed in the first half of the menstrual cycle, preferably between days 10 and 20 from the start of the last period. In this period, cervical epithelial cells are most representative for diagnostics. Before LBC swabbing, no vaginal irrigation, topical medications (suppositories, creams, gels), intimate deodorants, or vaginal preparations should be used for at least 2–3 days, as these may alter the sample composition or falsify results. Also, sexual intercourse should be avoided for at least 24–48 hours before the test, as well as the procedure itself avoided during menstruation or heavy discharge. Inform your gynecologist about medication use, prior procedures, unusual symptoms or complaints, enabling them to plan and rule out possible contraindications. If there is a genital infection (for example, acute inflammation), testing is best done after successful treatment, as the presence of pus or blood may impair cytopathological assessment. Sample collection for LBC is non-invasive, fast, and takes only a few minutes – the doctor or midwife uses a special brush placed into the cervical canal. The collected cells are placed directly into the fixative, preventing drying and allowing precise lab analysis.
Interpretation of LBC cytology typically uses the Bethesda classification, which divides results into main categories, allowing assessment of cervical health and need for further study. A normal outcome is most often labeled NILM (Negative for Intraepithelial Lesion or Malignancy), meaning no pathological or cancerous changes. In such cases, retesting at the recommended interval, usually every 3 years, is advised. If cytology reveals abnormalities, terms such as ASC-US (atypical squamous cells of undetermined significance), LSIL (low-grade intraepithelial lesion), HSIL (high-grade), or more advanced findings indicating malignant cells may appear. The detection of abnormal cells does not always mean developing cancer – in many situations further diagnostic work-up is needed, such as colposcopy, HPV testing, or additional molecular procedures. Results may also indicate inflammatory states, bacterial, viral (e.g. HPV, HSV-2), or fungal infections, which is important for medical management and ongoing monitoring. Minor cytological abnormalities can be observed and followed with periodic checkups, while higher-risk changes generally require prompt diagnostics and possible treatment to halt the precancerous process. Accurate interpretation, causal assessment, and cooperation with your gynecologist are vital to effective cervical cancer prevention and lifelong intimate health. Remember, LBC’s higher sensitivity detects more precancerous changes than classic cytology, increasing diagnostic safety even in symptomless women.
Summary
Liquid-based cytology (LBC) combined with HPV testing is the most modern and effective method for preventing and early detection of cervical cancer. It not only detects precancerous changes, but also other genital infections such as HPV, bacterial, or fungal infections. These tests are distinguished by high sensitivity and the possibility to perform them under the NFZ. Regular LBC and HPV testing, proper preparation, and result interpretation form the cornerstone of intimate health for every woman.
